Stock Analysis
CRISPR Therapeutics AG (CRSP) Stock Analysis
CRISPR Therapeutics AG (CRSP) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
CRISPR Therapeutics AG (CRSP) currently has an AIQ Score of 36/100, indicating a bearish setup. Momentum is the strongest factor at 52/100. Quality is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CRSP at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $51.42 |
| AIQ Score | 36/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Buy |
| Market Cap | $5.48B |
| P/E Ratio (TTM) | -11.94 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.94 |
| Revenue (quarter ended 2026-06-30) | $10.18M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.74 |
| Volume | 1.17M |
| 52-week range | $44.12-$65.98 |
| RSI 14 | 52.84 |
| 50-Day SMA | $54.32 |
| 200-Day SMA | $52.91 |
| Analyst Price Target | $65.57 |
| Next Earnings | Nov 9, 2026 |
CRSPCRISPR Therapeutics AG
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum52
- Value34
- Quality23
- Risk resilience40
- Sentiment—
CRSP Stock Analysis Summary
CRISPR Therapeutics AG (CRSP) currently has an AIQ Score of 36/100, indicating a bearish setup. Momentum is the strongest factor at 52/100. Quality is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, CRSP has AIQ Score of 36/100 with Momentum base of 52/100 and fading Quality at 23/100. Wait for component alignment before adding exposure.
Momentum (52/100) leads while Quality (23/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -5.23% stock move · CRSP classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CRSP Bullish or Bearish Right Now?
CRSP currently has a bearish overall setup. Momentum is the strongest factor at 52/100, while Quality is weakest at 23/100. The current evidence suggests a defensive setup.
- - Analyst target implies +27.52% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (31 vs 10).
- - Value is the current constraint at 34/100.
- - Risk Resilience is weak at 40/100.
Current Consensus
CRSP's Technical Analysis Consensus is currently Buy, with 31 buy, 4 neutral, and 10 sell votes. CRSP's 14-day RSI is 52.84, which places the stock in a neutral momentum range. CRSP's beta is 1.74, indicating greater market sensitivity than the broad market.
What Changed in CRSP?
The largest recent change in CRSP is Momentum moving up by 22.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the CRSP Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CRSP Decision Framework
Public evidence layers, setup checks, and risk context for CRISPR Therapeutics AG.
CRISPR Therapeutics AG (CRSP) Stock Analysis
CRISPR Therapeutics AG has an AIQ Score of 36/100 in a Defensive regime. Momentum is strongest at 52/100. Beta is 1.76, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CRSP is in a Defensive AIQ regime with score 36/100. |
| Signal Conflict | The primary conflict is that momentum leads at 52/100 while quality lags at 23/100. |
| Factor Evidence | Momentum 52/100 · Value 34/100 · Quality 23/100 · Risk 40/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 52/100.
Momentum is 52/100 and RSI (14) is 52.8.
CRSP is in a Defensive regime at 36/100.
Risk factor is 40/100 with beta 1.76 and annual volatility 57.59%.
Current conflict: momentum leads at 52/100 while quality lags at 23/100.
CRSP Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CRSP Fundamentals
CRSP valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CRSP Technical Analysis
CRSP technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CRSP Stock Catalysts
Track CRSP earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CRSP Dividend Analysis
CRSP dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CRSP Financial Data
CRSP revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CRSP Risk Analysis
CRSP volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CRSP Stock News
CRSP stock news, market tone, recent headlines, and catalyst context.
CRSP vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: CRSP · DNLI · DTIL · EDIT · FATE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CRSP Current stock | 36/100 | 34/100 | 52/100 | 40/100 | -0.03 | 57.59% | Current |
| DNLI Denali Therapeutics | 40/100 | 34/100 | 41/100 | 67/100 | 0.52 | 55.12% | CRSP vs DNLI |
| DTIL Precision BioSciences | 58/100 | 60/100 | 70/100 | 51/100 | 0.11 | 69.22% | CRSP vs DTIL |
| EDIT Editas Medicine | 48/100 | 34/100 | 63/100 | 39/100 | 0.31 | 81.95% | CRSP vs EDIT |
| FATE Fate Therapeutics | 34/100 | 34/100 | 48/100 | 34/100 | 0.93 | 88.75% | CRSP vs FATE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CRSP
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CRSP
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CRSP Stock FAQ
What is CRSP stock price today?
CRISPR Therapeutics AG's current stock price is $51.42. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CRSP bullish or bearish right now?
CRSP's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CRSP's market cap?
CRSP's market cap is $5.48B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CRSP's current P/E ratio?
CRSP's current P/E ratio is -11.94 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CRSP's RSI?
CRSP's 14-day RSI is 52.84 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CRSP above its 50-day and 200-day moving averages?
CRSP is -0.12% from its 50-day SMA and 2.55% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CRSP's next earnings date?
CRSP's next earnings date is currently listed as Nov 9, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CRSP pay a dividend?
CRSP's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.